Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans

Journal of Controlled Release

Volumn 113, Issue 3, 2006, Pages 208-215

  Kagan, Leonid ^a   Lapidot, Noa ^b   Afargan, Michel ^b   Kirmayer, David ^b   Moor, Eytan ^a,b   Mardor, Yael ^c   Friedman, Michael ^a   Hoffman, Amnon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Intec Pharma Ltd   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Controlled release; Gastric residence time; Narrow absorption window; Pharmacokinetics; Saturable absorption

Indexed keywords

ABSORPTION; ASSAYS; BLOOD; CALORIFIC VALUE; DRUG DOSAGE; DRUG PRODUCTS; MAGNETIC RESONANCE IMAGING; PHARMACOKINETICS; RADIOFREQUENCY SPECTROSCOPY;

CONTROLLED RELEASE; GASTRIC RESIDENCE TIME (GRT); NARROW ABSORPTION WINDOW; SATURABLE ABSORPTION;

GASTROENTEROLOGY;

ACCORDION PILL; DRUG VEHICLE; FLAVINE MONONUCLEOTIDE; UNCLASSIFIED DRUG;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG TRANSPORT; FEMALE; GASTRIC RESIDENCE TIME; GASTRORETENTIVE DOSAGE FORM; HUMAN; HUMAN EXPERIMENT; LOW CALORY DIET; MALE; METABOLIC CLEARANCE RATE; MODEL; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PILL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UPPER GASTROINTESTINAL TRACT; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CAPSULES; DELAYED-ACTION PREPARATIONS; FEMALE; FERROSOFERRIC OXIDE; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE IMAGING; MALE; RIBOFLAVIN; SOLUBILITY; STOMACH; VITAMIN B COMPLEX;

EID: 33745494695     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.03.022     Document Type: Article

References (31)

1. Davis S.S. Formulation strategies for absorption windows. Drug Discov. Today 10 4 (2005) 249-257
2. A. Hoffman, E. Lavy, E. Klausner, M. Friedman, Gastroretentive controlled release pharmaceutical dosage forms. Patent US 6685962, 2004.
3. Hoffman A., Stepensky D., Lavy E., Eyal S., Klausner E., and Friedman M. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int. J. Pharm. 277 1-2 (2004) 141-153
4. Moes A.J. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carr. Syst. 10 2 (1993) 143-195
5. Reddy L.H., and Murthy R.S. Floating dosage systems in drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 19 6 (2002) 553-585
6. Hou S.Y., Cowles V.E., and Berner B. Gastric retentive dosage forms: a review. Crit. Rev. Ther. Drug Carr. Syst. 20 6 (2003) 459-497
7. Washington N., Washington C., and Wilson C.G. Physiological pharmaceutics. Barriers to drug absorption (2001), Taylor and Francis Inc, New York 75-108
8. Deshpande A.A., Rhodes C.T., Shah N.H., and Malick A.W. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev. Ind. Pharm. 22 6 (1996) 531-539
9. Klausner E.A., Lavy E., Friedman M., and Hoffman A. Expandable gastroretentive dosage forms. J. Control. Release 90 2 (2003) 143-162
10. Deshpande A.A., Shah N.H., Rhodes C.T., and Malick W. Development of a novel controlled-release system for gastric retention. Pharm. Res. 14 6 (1997) 815-819
11. Talukder R., and Fassihi R. Gastroretentive delivery systems: hollow beads. Drug Dev. Ind. Pharm. 30 4 (2004) 405-412
12. Srivastava A.K., Ridhurkar D.N., and Wadhwa S. Floating microspheres of cimetidine: formulation, characterization and in-vitro evaluation. Acta Pharm. 55 (2005) 277-285
13. Umamaheshwari R.B., Jain S., and Jain N.K. A new approach in gastroretentive drug delivery system using cholestyramine. Drug Deliv. 10 3 (2003) 151-160
14. Fix J.A., Cargill R., and Engle K. Controlled gastric emptying. III. Gastric residence time of a nondisintegrating geometric shape in human volunteers. Pharm. Res. 10 7 (1993) 1087-1089
15. Chen J., Blevins W.E., Park H., and Park K. Gastric retention properties of superporous hydrogel composites. J. Control. Release 64 1-3 (2000) 39-51
16. Davis S.S., Wilding E.A., and Wilding I.R. Gastrointestinal transit of a matrix tablet formulation: comparison of canine and human data. Int. J. Pharm. 94 1-3 (1993) 235-238
17. B. Qadry, A. Hoffman, in: J. Swarbrick (Ed.), Encyclopedia of Pharmaceutical Technology, Taylor and Francis Group, New York, in press.
18. Gusler G., Hou S.Y.E., Berner B., Enriquez A., Low C., Levy G., Dye D., Chau M., Zhang S., Shell J.N., Lim J., Cowles V., Muller M., Stiff D., Pabst G., and Baumeister A. Single-Dose Pharmacokinetics of Gabapentin Gastric Retentive (GR ) Tablets in Healthy Volunteers. Controlled Release Society 31st Annual Meeting (2004)
19. Klausner E.A., Eyal S., Lavy E., Friedman M., and Hoffman A. Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J. Control. Release 88 1 (2003) 117-126
20. Klausner E.A., Lavy E., Barta M., Cserepes E., Friedman M., and Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm. Res. 20 9 (2003) 1466-1473
21. Klausner E.A., Lavy E., Stepensky D., Cserepes E., Barta M., Friedman M., and Hoffman A. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. J. Clin. Pharmacol. 43 7 (2003) 711-720
22. Klausner E.A., Lavy E., Stepensky D., Friedman M., and Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm. Res. 19 10 (2002) 1516-1523
23. Hoffman A., Lavy E., Klausner E., Afargan M., Fass S., and Friedman M. A Novel Controlled Release Gastroretentive Dosage Form: Design and Clinical Results in Radiology, L-DOPA and Furosemide (2004), Controlled Release Society 31nd Annual Meeting
24. Hoffman A., Afargan M., Tzabari M., Mor E., Kagan L., Kirmayer D., Fass S., Lapidot N., Mardor Y., and Friedman M. An innovative platform for gastric retention and controlled release of drugs under low calorie diet: gastroretentivity evaluation using MRI. Controlled Release Society 32nd Annual Meeting and Exposition, Miami USA (2005)
25. Jusko W.J., and Levy G. Absorption, metabolism, and excretion of riboflavin-5'-phosphate in man. J. Pharm. Sci. 56 1 (1967) 58-62
26. Levy G., and Jusko W.J. Factors affecting the absorption of riboflavin in man. J. Pharm. Sci. 55 3 (1966) 285-289
27. Steingoetter A., Weishaupt D., Kunz P., Mäder K., Lengsfeld H., Thumshirn M., Boesiger P., Fried M., and Schwizer W. Magnetic resonance imaging for the in-vivo evaluation of gastric-retentive tablets. Pharm. Res. 20 12 (2003) 2001-2007
28. Gatautis V.J., and Naito H.K. Liquid-chromatographic determination of urinary riboflavin. Clin. Chem. 27 10 (1981) 1672-1675
29. Zempleni J., Link G., and Kubler W. The transport of thiamine, riboflavin and pyridoxal 5'-phosphate by human placenta. Int. J. Vitam. Nutr. Res. 62 2 (1992) 165-172
30. Capo Chichi C.D., Gueant J.L., Lefebvre E., Bennani N., Lorentz E., Vidailhet C., and Vidailhet M. Riboflavin and riboflavin-derived cofactors in adolescent girls with anorexia nervosa. Am. J. Clin. Nutr. 69 4 (1999) 672-678
31. Whitehead L., Fell J.T., Collett J.H., Sharma H.L., and Smith A. Floating dosage forms: an in-vivo study demonstrating prolonged gastric retention. J. Control. Release 55 1 (1998) 3-12